None listed
Conditions
Interventions
None listed
Sponsors
Soon Chun Hyang University Hospital Bucheon
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) 19 years of age or older 2) Histologically confirmed gastric adenocarcinoma 3) Patients who have been treated with weekly paclitaxel and ramucirumab combination therapy as palliative second-line systemic chemotherapy, or who have relapsed during or within 6 months of XELOX adjuvant chemotherapy after surgery and have been treated with weekly paclitaxel and ramucirumab 4) Patients who have received immune checkpoint chemotherapy (nivolumab or pembrolizumab) or irinotecan-based cytotoxic chemotherapy (irinotecan alone or FOLFIRI therapy) as third-line chemotherapy 5) Patients who received fluropyrimidine plus platinum+/-trastuzumab as primary anticancer treatment
Exclusion criteria
Exclusion criteria: 1) Patients who have metastatic cancer other than stomach cancer 2) Patients treated with irinotecan, nivolumab, or pembrolizumab as first-line or second-line palliative chemotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall suvival | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival, overall response rate, adverse events | — |
Countries
Korea, Republic of
Contacts
Public ContactSung Hee Lim
Soon Chun Hyang University Hospital Bucheon
Outcome results
None listed